## Clinical Context This patient has stage 3b chronic kidney disease (eGFR 28 mL/min/1.73 m²) with diabetic nephropathy, evidenced by proteinuria, hypertension, and progressive decline in renal function over 2 years. ## Rationale for Correct Answer **Key Point:** At eGFR 28 mL/min/1.73 m² with proteinuria, the priority is slowing progression of renal disease through renin-angiotensin-aldosterone system (RAAS) inhibition and cardio-renal protection. **High-Yield:** SGLT2 inhibitors (empagliflozin, dapagliflozin) have proven benefits in diabetic kidney disease: - Reduce albuminuria independent of glucose control - Slow GFR decline - Reduce cardiovascular and renal mortality - Effective across all stages of CKD (including stage 3b) **Clinical Pearl:** ACE inhibitors or ARBs are first-line agents for diabetic nephropathy with proteinuria. SGLT2 inhibitors provide additive renoprotection and should be added early, even before stage 4 CKD. ## Why This Stage Requires This Approach | Stage | eGFR Range | Management Focus | | --- | --- | --- | | Stage 3a | 45–59 | Optimize BP, RAAS inhibition, monitor | | Stage 3b | 30–44 | Add SGLT2i, optimize ACEi/ARB, prepare for CKD complications | | Stage 4 | 15–29 | Prepare for RRT, manage mineral-bone disease | | Stage 5 | <15 | Initiate dialysis or transplant | This patient is at stage 3b and has not yet reached the threshold for dialysis preparation (stage 4–5). ## Algorithm for Diabetic CKD Management ```mermaid flowchart TD A[Type 2 DM + Proteinuria]:::outcome --> B{eGFR?}:::decision B -->|≥45| C[ACEi/ARB + optimize BP]:::action B -->|30-44| D[ACEi/ARB + SGLT2i + optimize BP]:::action B -->|15-29| E[Prepare for RRT + manage complications]:::action B -->|<15| F[Initiate dialysis/transplant]:::action D --> G[Monitor eGFR, proteinuria q3mo]:::action ```
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.